Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Extrahepatic bile duct cancer
Stage/Subtype:  metastatic extrahepatic bile duct cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-11 of 11 for your search:
Start Over
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SPI-1620-12-202, NCI-2013-01789, NCT01773785
Regorafenib in Treating Patients With Advanced or Metastatic Biliary Tract Cancer Who Failed First-Line Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-100, NCI-2014-01117, NCT02053376
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17651, NCI-2014-00956, 14.02.0015, NCT02115542
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RRx001-27-01, NCI-2015-00944, NCT02452970
Sorafenib Tosylate and Capecitabine in Treating Patients With Advanced Breast or Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HIC # 1112009424, NCI-2013-00893, 1112009424, ONC-2010-35, NCT01640665
Combination Chemotherapy in Treating Patients With Previously Untreated Locally Advanced or Metastatic Gastrointestinal Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0033, NCI-2012-00585, 12-0033-AM010, NCT01643499
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
6,8-Bis(benzylthio)octanoic Acid in Treating Patients with Advanced or Metastatic Cholangiocarcinoma that Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 18 to 80
Trial IDs: CCCWFU 59212, NCI-2013-00063, NCT01766219
Start Over